Scholz D, Schwille P O, Sigel A
J Urol. 1982 Nov;128(5):903-7. doi: 10.1016/s0022-5347(17)53269-3.
The effect of 25 mg. hydrochlorothiazide twice daily on the meta-phylaxis of recurrent calcium lithiasis was compared to placebo in a double-blind study during 1 year in 51 patients. A distinct and continuous decrease in urinary calcium excretion occurred only in patients given hyrochlorothiazide. On the other hand, both groups showed a slight increase in total serum calcium levels, unchanged values for ionized and ultrafilterable calcium, and decreased urinary excretion of oxalate during the study. The activity products of calcium oxalate and calcium phosphate also were decreased in both groups but remained within the metastable range. Spontaneous passage of renal stones occurred during treatment in 6 patients given placebo and in 6 treated with hydrochlorothiazide despite decreased urinary calcium excretion in the latter group. The findings show the specific effect of hydrochlorothiazide treatment to be a decrease in urinary calcium excretion in patients with calcium lithiasis, while other changes appear to be nonspecific effects of treatment.
在一项针对51例患者的为期1年的双盲研究中,将每日两次服用25毫克氢氯噻嗪对复发性钙结石病的预防效果与安慰剂进行了比较。仅在服用氢氯噻嗪的患者中,尿钙排泄出现了明显且持续的下降。另一方面,在研究期间,两组患者的总血清钙水平均略有升高,离子化钙和可超滤钙的值未变,草酸盐的尿排泄减少。两组草酸钙和磷酸钙的活性产物也均降低,但仍处于亚稳范围内。尽管服用氢氯噻嗪的后一组患者尿钙排泄减少,但在治疗期间,服用安慰剂的6例患者和服用氢氯噻嗪治疗的6例患者均出现了肾结石的自然排出。研究结果表明,氢氯噻嗪治疗的特定效果是降低钙结石病患者的尿钙排泄,而其他变化似乎是治疗的非特异性效果。